Partner Article
Wirral's Biofortuna raise £1.3m for expansion
Wirral-based molecular diagnostics outfit, Biofortuna, has raised £1.3m to expand its manufacturing.
The funding was supported by the company’s current investors, including the Foresight Group (UK), Enterprise Ventures Group, Catapult Venture Managers, Merseyside Special Investment Fund, private investors and management.
It will be used to expand Biofortuna’s analysis of freeze drying diagnostic products.
The Bromborough-based business has developed technology that allows DNA tests to be premixed and freeze dried, for a simpler and cost effective process.
Dr Simon Douglas, CEO of Biofortuna said: “This investment will enable Biofortuna to grow its freeze dried development and manufacturing capacity.
“With an increasing number of companies coming to us to stabilise their products we need to expand our freeze drying capability to complement our already established diagnostic development expertise.
“I am delighted that Biofortuna has received continued support from its current investors who share the enthusiasm and vision of the management team.”
This was posted in Bdaily's Members' News section by Tom Keighley .
How businesses can reduce workplace safety risks with custom solutions
Tech firm unveils jobs plan after £530,000 backing
SMEs urged to think big at Newcastle event
B Corp is a commitment, not a one-time win
Government must get in gear on vehicle transition
A legacy in stone and spirit
Shaping the future: Your guide to planning reforms
The future direction of expert witness services
Getting people into gear for a workplace return
What to expect in the Spring Statement
Sunderland leading way in UK office supply market
Key construction developments in 2025